The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index; none of the 13 sources its claims cite is checked for support yet.
Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy†
Open accessAbstract
Severe lipodystrophy is characterized by diminished adipose tissue and hypoleptinemia, leading to ectopic triglyceride accumulation. In the liver, this is associated with steatosis, potentially leading to nonalcoholic steatohepatitis (NASH). We investigated the prevalence of NASH and the effect of leptin replacement in these patients. Ten patients with either generalized lipodystrophy (8 patients) or Dunnigan's partial lipodystrophy (2 patients) were included in this analysis. Paired liver biopsy specimens were obtained at baseline and after treatment with recombinant methionyl human leptin (r-metHuLeptin), mean duration 6.6 months. The extents of portal and parenchymal inflammation, steatosis, ballooning, presence of Mallory bodies, and fibrosis in liver biopsy specimens were scored using a previously validated system developed to assess NASH activity. Histological disease activity was defined as the sum of ballooning, steatosis, and parenchymal inflammation scores. We concurrently tested serum triglycerides and aminotransferases and estimations of liver volume and fat content by magnetic resonance imaging. Eight of 10 patients met histological criteria for NASH at baseline. After treatment with r-metHuLeptin, repeat histological examinations showed significant improvements in steatosis (P = .006) and ballooning injury (P = .005), with a reduction of mean NASH activity by 60% (P = .002). Fibrosis was unchanged. Significant reductions were seen in mean serum triglycerides (1206-->226 mg/dL, P = .002), glucose (220-->144 mg/dL, P = .02), insulin (46.4-->24.8 muIU/mL, P = .004), ALT (54-->24 U/L, P = .02), AST (47-->22 U/L, P = .046), liver volume (3209-->2391 cm(3), P = .007), and liver fat content (31-->11%, P = .006). In conclusion, r-metHuLeptin therapy significantly reduced triglycerides, transaminases, hepatomegaly, and liver fat content. These reductions were associated with significant reductions in steatosis and the hepatocellular ballooning injury seen in NASH.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In 10 patients with severe lipodystrophy and hypoleptinemia, recombinant methionyl human leptin (r-metHuLeptin) treatment was associated with significant histological improvement in nonalcoholic steatohepatitis (NASH), alongside reductions in liver fat, liver volume, triglycerides, and aminotransferases. Fibrosis did not change over the mean 6.6-month treatment period.
Key findings
- Eight of 10 patients met histological criteria for NASH at baseline; after r-metHuLeptin, 6 of the 8 (75%) no longer met those criteria, and the group prevalence of NASH fell from 80% to 20% (P = .03).
- Mean NASH activity score decreased by 60%, from 5.3 ± 0.8 to 2.1 ± 0.4 (P = .002), with significant improvements in steatosis (1.7 ± 0.4 to 0.4 ± 0.2; P = .006) and ballooning injury (1.5 ± 0.4 to 0.3 ± 0.2; P = .005); fibrosis was unchanged (1.9 ± 0.4 to 1.9 ± 0.5; P = .1).
- Mean serum triglycerides fell from 1,206 ± 590 to 226 ± 57 mg/dL (P = .002), fasting glucose from 220 ± 27 to 144 ± 13 mg/dL (P = .02), fasting insulin from 46.4 ± 13.0 to 24.8 ± 7.4 IU/mL (P = .004), ALT from 54 ± 13 to 24 ± 4 U/L (P = .02), and AST from 47 ± 11 to 22 ± 2 U/L (P = .046).
- Mean liver volume decreased from 3,209 ± 348 to 2,391 ± 254 cm³ (P = .007), and mean liver fat by MRI decreased from 31% ± 7% to 11% ± 6% (P = .006).
Methods
- Open-label pilot study of r-metHuLeptin in 10 patients with severe lipodystrophy: 4 congenital generalized lipodystrophy, 4 acquired generalized lipodystrophy, and 2 Dunnigan’s partial lipodystrophy; 8 female and 2 male, age range 17–67 years.
- Paired liver biopsies were obtained before and after treatment (mean duration 6.6 ± 1.4 months); biopsies were scored by a single hepatopathologist blinded to clinical data and biopsy sequence using a previously validated NASH scoring system.
- Concurrent laboratory testing and MRI assessments of liver volume and liver fat were performed; paired t tests or Wilcoxon signed-rank tests compared baseline and post-treatment means, and Spearman rank correlation assessed relationships between NASH score and metabolic/imaging variables.
Limitations
- The paper states limitations including relatively small sample size, variable interval between liver biopsies, study of a rare disease with uncertain general relationship to NASH, lack of placebo control, and no evidence that results in hypoleptinemic patients apply to broader NASH patients with higher serum leptin concentrations.
- The authors also state that the short interval between biopsies was the primary factor limiting observed change in fibrosis.
- Evident from the text: this was an open-label, single-arm pilot study without a placebo or untreated comparator, and the sample was predominantly female, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
23 Own result · 12 Own interpretation · 7 Not checked yet · 5 Own method
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fasting insulin (IU/mL) 46.4 Ϯ 13.0 24.8 Ϯ 7.4 .004”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The reductions in NASH scores were strongly correlated with reductions in liver volumes, liver fat measured by MRI, serum transami-nases, triglycerides, fasting insulin, and fasting glucose values (Table 3).”
- Also stated in: § Discussion · plain
“There were significant correlations between the NASH activity scores and MRI estimations of liver volume and fat content, serum transaminases, triglycerides, fasting insulin, and fasting glucose values.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > r-metHuLeptin Therapy
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ALT (U/L) 54 Ϯ 13 24 Ϯ 4 .02”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fasting glucose (mg/dL) 220 Ϯ 27 144 Ϯ 13 .02”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After treatment with r-metHuLeptin, repeat histological examinations showed significant improvements in steatosis (P ؍ .006)and ballooning injury (P ؍ .005),with a reduction of mean NASH activity by 60% (P ؍ .002).”
- Also stated in: § Discussion · plain
“Steatosis 1.7 Ϯ 0.4 0.4 Ϯ 0.2 .006”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Abstract
plaindirectn = 10 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Liver volume (cc) 3,209 Ϯ 348 2,391 Ϯ 254 .007”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Eight of 10 patients met histological criteria for NASH at baseline.”
- Also stated in: § Baseline Liver Data · plain
“Eight patients had histological evidence of NASH.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Abstract
plainn = 10- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Baseline Liver Data · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After treatment with r-metHuLeptin, repeat histological examinations showed significant improvements in steatosis (P ؍ .006)and ballooning injury (P ؍ .005),with a reduction of mean NASH activity by 60% (P ؍ .002).”
- Also stated in: § Discussion · plain
“Ballooning injury 1.5 Ϯ 0.4 0.3 Ϯ 0.2 .005”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Abstract
plaindirectn = 10 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“HbA 1c (%) 8.5 Ϯ 0.3 6.7 Ϯ 0.4 .005”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 9 patients who had steatosis at baseline, only 3 had steatosis on follow-up biopsy.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > r-metHuLeptin Therapy
plainn = 9- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 3
- Probably not a substantial claim. 18
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly, of the 8 patients with ballooning hepatocellular injury, only 3 had ballooning identified in follow-up, and in all 3 the degree was mild and confined to zone 3.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > r-metHuLeptin Therapy
plainn = 8- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mallory bodies 0.6 Ϯ 0.3 0.2 Ϯ 0.2 .1”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition to steatosis and inflammation, all 8 patients with steatohepatitis had ballooning hepatocellular injury varying from mild changes only in zone 3 to diffuse, panacinar ballooning changes and fibrosis that varied from mild perisinusoidal zone 3 fibrosis to cirrhosis.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Baseline Liver Data
plainn = 8- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Only 3 patients had identifiable Mallory bodies, despite staining all biopsy specimens with anti-ubiquitin.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Baseline Liver Data
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, the causative relationship of these correlations to the clinical situation remains uncertain.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A liver specimen of at least 15 mm with a minimum of 10 portal tracts was considered adequate for evaluation.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Histological Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The modified Dixon method was used to assess the hepatic fat fraction.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Liver Fat Measurements.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The extents of portal and parenchymal inflammation, steatosis, ballooning, presence of Mallory bodies, and fibrosis in liver biopsy specimens were scored using a previously validated system developed to assess NASH activity.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Abstract
What the sources say
- Not checked yetcites [14] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Steatosis is believed to sensitize the liver to metabolic injury, leading to inflammation, necrosis, and fibrosis.2,[5][6][7]”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Abstract
What the sources say
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Biopsy specimens were scored prospectively by a single hepatopathologist blinded to the clinical data and sequence of the biopsies using a previously described scoring method developed for NASH.14”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Histological Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“The assessment and severity of NASH is made histologically based on the patterns and degrees of hepatic steatosis, inflammation, and injury, in the absence of significant alcohol consumption.8”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Abstract
What the sources say
- Not checked yetcites [8] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Other limitations of this study include its relatively small sample size, the variable interval between liver biopsies, the study of a rare disease in terms of its general relationship to NASH, and the fact that this study was not placebo-controlled.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Recent rodent studies suggest that this can be potentially overcome with a high enough dose, 22,24 a theory similar to insulin resistance.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Severe lipodystrophy is an exaggerated model of ectopic fat accumulation leading to an exaggerated form of the metabolic syndrome.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This may have broader implications for NASH in the general population, which is also characterized by ectopic triglyceride accumulation and secondary disorders such as insulin resistance.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Other limitations of this study include its relatively small sample size, the variable interval between liver biopsies, the study of a rare disease in terms of its general relationship to NASH, and the fact that this study was not placebo-controlled.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The leptin and thiazolidinedione models both demonstrate the association of NASH with steatosis and the reversal of NASH by removing the fat.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, we have no evidence that the results achieved in this population of patients with hypoleptinemia are relevant to the broader group of NASH patients with higher serum leptin concentrations.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Other limitations of this study include its relatively small sample size, the variable interval between liver biopsies, the study of a rare disease in terms of its general relationship to NASH, and the fact that this study was not placebo-controlled.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In other words, insulin resistance and NASH appear to develop in parallel rather than sequentially.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Other limitations of this study include its relatively small sample size, the variable interval between liver biopsies, the study of a rare disease in terms of its general relationship to NASH, and the fact that this study was not placebo-controlled.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
Severe lipodystrophy is characterized by diminished adipose tissue and hypoleptinemia, leading to ectopic triglyceride accumulation.
“Severe lipodystrophy is characterized by diminished adipose tissue and hypoleptinemia, leading to ectopic triglyceride accumulation.”
The paper relies on this without support.
In the absence of adequate adipose tissue, combined with leptin deficiency, the liver becomes a major repository for triglycerides in lipodystrophic patients, often expanding far beyond the normal size.
“In the absence of adequate adipose tissue, combined with leptin deficiency, the liver becomes a major repository for triglycerides in lipodystrophic patients, often expanding far beyond the normal size.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“leptin therapy has been examined in several clinical trials in patients with lipodystrophy and these have demonstrated significant improvements in glycemia, dyslipidemia and hepatic steatosis (89, 90, 139, 142).”
From Leptin and the Central Nervous System Control of Glucose Metabolism (2011) · cites this paper as [90]
In the citing paper
“The reduction of hepatomegaly was associated with improvement of nonalcoholic steatohepatitis, a severe inflammatory manifestation of NAFLD (12).”
From Long-Term Efficacy of Leptin Replacement in Patients With Generalized Lipodystrophy (2005) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Liver fat by MRI (%) 31 Ϯ 7 1 1 Ϯ 6 .006”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
Reported 31 · recomputed 57.1
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Patient Population and Study Design
“They ranged in age from 17 to 67 years.”
§ Leptin Reverses Nonalcoholic Steatohepatitis in Patients With Severe Lipodystrophy > Discussion
“Age/sex (y/M/F) 17/F 36/F 42/F 40/F 64/F 35/M 68/M”
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell, B., Scarpulla, R. C., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80611-x · Cited by 4,139
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,564
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes
Petersen, K. F., Dufour, S., Befroy, D., Garcia, R., & Shulman, G. I. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031314 · Cited by 2,193
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Leptin-Replacement Therapy for Lipodystrophy
Oral, E. A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A. J., DePaoli, A. M., Reitman, M. L., Taylor, S. I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012437 · Cited by 1,247
Self-citationOkuno, A., Tamemoto, H., Kazuuki, T. O. B. E., Ueki, K., Mori, Y., Iwamoto, K., Umesono, K., Akanuma, Y., Fujiwara, T., Horikoshi, H., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1235 · Cited by 995
Adams, L. A., Sanderson, S. O., Lindor, K. D., & Angulo, P. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 912
Unger, R. H. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104057 · Cited by 875
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
Petersen, K. F., Oral, E. A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. W., DePaoli, A. M., Taylor, S. I., Gorden, P., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215001 · Cited by 800
Neuschwander‐Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1053/jhep.2003.50420 · Cited by 744
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726
Self-citationGavrilova, O., Haluzik, M., Matsusue, K., Cutson, J. J., Johnson, L., Dietz, K. R., Nicol, C. J., Vinson, C., Gonzalez, F. J., & Reitman, M. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300043200 · Cited by 707
Selective deletion of leptin receptor in neurons leads to obesity
Cohen, P., Zhao, C., Cai, X., Montez, J. M., Rohani, S., Feinstein, P. G., Mombaerts, P., & Friedman, J. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13914 · Cited by 664
Selective deletion of leptin receptor in neurons leads to obesity
Cohen, P., Zhao, C., Cai, X., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200113914 · Cited by 554
Molecular Virology of Hepatitis B Virus
LOCARNINI, S. A. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-828672 · Cited by 521
(2004) · Seminars in Liver Disease · doi:10.1055/s-2004-823098 · Cited by 481
Leptin is essential for the hepatic fibrogenic response to chronic liver injury
Leclercq, I. A., Farrell, G. C., Schriemer, R., & Robertson, G. R. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00102-2 · Cited by 407
Fatty liver hepatitis and cirrhosis in obese patients
Adler, M., & Schaffner, F. (1979) · The American Journal of Medicine · doi:10.1016/0002-9343(79)90740-x · Cited by 399
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., & Sheppard, B. L. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03553.x · Cited by 394
Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes
Arioglu, E., Duncan-Morin, J., Sebring, N., Rother, K. I., Gottlieb, N., Lieberman, J., Herion, D., Kleiner, D. E., Reynolds, J., Premkumar, A., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-4-200008150-00009 · Cited by 303
Self-citationIkejima, K., Honda, H., Yoshikawa, M., Hirose, M., Kitamura, T., Takei, Y., & Sato, N. (2001) · Hepatology · doi:10.1053/jhep.2001.26518 · Cited by 292
Bajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L. J., Pratipanawatr, W., Glass, L. C., Cersósimo, E., Miyazaki, Y., & DeFronzo, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1364 · Cited by 291
Non‐alcoholic steatohepatitis: another disease of affluence
James, *., & Day, C. (1999) · The Lancet · doi:10.1016/s0140-6736(99)00163-4 · Cited by 271
Musso, C., Cochran, E., Moran, S. A., Skarulis, M. C., Oral, E. A., Taylor, S., & Gorden, P. (2004) · Medicine · doi:10.1097/01.md.0000133625.73570.54 · Cited by 264
Self-citationRapid transformation of white adipocytes into fat-oxidizing machines
Orci, L., Cook, W. S., Ravazzola, M., Wang, M.-Y., Park, B.-H., Montesano, R., & Unger, R. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308258100 · Cited by 234
Introduction of fast MR imaging in the assessment of hepatic steatosis
Fishbein, M. H., Gardner, K. G., Potter, C. J., Schmalbrock, P., & Smith, M. A. (1997) · Magnetic Resonance Imaging · doi:10.1016/s0730-725x(96)00224-x · Cited by 226
ARIOGLU, E., ANDEWELT, A., DIABO, C., BELL, M., TAYLOR, S. I., & GORDEN, P. (2002) · Medicine · doi:10.1097/00005792-200203000-00001 · Cited by 223
Site and mechanism of leptin action in a rodent form of congenital lipodystrophy
Asilmaz, E., Cohen, P., Miyazaki, M., Dobrzyn, P., Ueki, K., Fayzikhodjaeva, G., Soukas, A. A., Kahn, C. R., Ntambi, J. M., Socci, N. D., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419511 · Cited by 210
Site and mechanism of leptin action in a rodent form of congenital lipodystrophy
Asilmaz, E., Cohen, P., Miyazaki, M., Dobrzyń, P., Ueki, K., Fayzikhodjaeva, G., Soukas, A. A., Kahn, C. R., Ntambi, J. M., Socci, N. D., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19511 · Cited by 209
Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease
Angulo, P., Alba, L. M., Petrovic, L. M., Adams, L. A., Lindor, K. D., & Jensen, M. D. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.020 · Cited by 198
PPARα is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue
Lee, Y., Yu, X., Gonzales, F., Mangelsdorf, D. J., Wang, M.-Y., Richardson, C., Witters, L. A., & Unger, R. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182420899 · Cited by 181
Non‐alcoholic steatohepatitis (NASH): where are we now and where are we going?
Day, C. P. (2002) · Gut · doi:10.1136/gut.50.5.585 · Cited by 181
Does Leptin Play A Role in The Pathogenesis of Human Nonalcoholic Steatohepatitis?
Chalasani, N., Crabb, D. W., Cummings, O. W., Kwo, P. Y., Asghar, A., Pandya, P., & Considine, R. V. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.08767.x · Cited by 148
MITCHELL, D. G., KIM, I., CHANG, T. S., VINITSKI, S., SAPONARO, S. A., EHRLICH, S. M., RIFKIN, M. D., & RUBIN, R. (1991) · Investigative Radiology · doi:10.1097/00004424-199112000-00002 · Cited by 131
Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy
Moran, S. A., Patten, N., Young, J. R., Cochran, E., Sebring, N., Reynolds, J., Premkumar, A., Depaoli, A. M., Skarulis, M. C., Oral, E. A., et al. (2004) · Metabolism · doi:10.1016/j.metabol.2003.10.019 · Cited by 96
Self-citationCochran, E., Young, J. R., Sebring, N., DePaoli, A., Oral, E. A., & Gorden, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031952 · Cited by 83
Self-citationTritos, N. A., Elmquist, J. K., W. Mastaitis, J., Flier, J. S., & Maratos-Flier, E. (1998) · Endocrinology · doi:10.1210/endo.139.11.6308 · Cited by 82
Poordad, F. F. (2004) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200411000-00002 · Cited by 16
Cited by
Sorted by citations
Stern, J. H., Rutkowski, J. M., & Scherer, P. E. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.04.011 · Cited by 1,031
“accumulation and decrease the severity of NASH in lipodystrophic patients (Javor et al., 2005).”
BackgroundInsulin resistance: a metabolic pathway to chronic liver disease
Bugianesi, E., McCullough, A. J., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20920 · Cited by 900
The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome
Lim, J. S., Mietus-Snyder, M., Valente, A., Schwarz, J.-M., & Lustig, R. H. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.41 · Cited by 771
“For instance, patients with lipodystrophy are not obese, but have high levels of intrahepatic lipid”
BackgroundDuell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727
Narrative Review: The Role of Leptin in Human Physiology: Emerging Clinical Applications
Kelesidis, T., Kelesidis, I., Chou, S. H.-H., & Mantzoros, C. S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-2-201001190-00008 · Cited by 693
“5%, improves hyperlipidemia (57, 58), and reverses hepatic steatosis (53, 54).”
Background
Metadata
- Authors
- Javor, E. D., Ghany, M. G., Cochran, E. K., Oral, E. A., DePaoli, A. M., Premkumar, A., Kleiner, D. E., & Gorden, P.
- Affiliations
- National Institutes of Health (US)
- Amgen (United States) (US)
- Corresponding author
- Javor, Edward D.
- Venue
- Hepatology
- Published
- 2005-04
- Volume
- 41
- Issue
- 4
- Pages
- 753-760
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2064309380
- Semantic Scholar
- ed56502ccbe96c2f2b6ef8670f3ba0436824e56d
- Cited by
- 228
- References
- 45
- Citations by year
- 2025: 10 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 12 · 2020: 9 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 7 · 2015: 12 · 2014: 19 · 2013: 14 · 2012: 16
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- nonalcoholic steatohepatitis, generalized lipodystrophy, hepatic steatosis, hepatocyte ballooning, liver fibrosis, serum triglycerides, transaminases, liver fat, hepatomegaly, hypoleptinemia
- MeSH terms
- Adolescent, Adult, Aged, Transaminases, Fatty Liver, Female, Hepatitis, Humans, Lipodystrophy, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Pilot Projects, Triglycerides, Hormone Replacement Therapy, Leptin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
